Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VVOS vs PACB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PACB Captures Overall Composite Edge (50.1 HOLD vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars
PACB Overall Winner
6-Pillar Tally: VVOS 3 – 2 PACB (1 Tie)
Matrix Metrics: VVOS 2 – 6 PACB
As of Nov 20, 2026, Pacific Biosciences of California, Inc. (PACB) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (50.1/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus PACB at $1.63 (N/M Forward P/E, -333.0% operating margin).
- Growth vs. Quality Trade-Off: PACB earns the overall head-to-head edge with a stronger Unified Composite Score (50.1/100 HOLD vs. VVOS 36.4/100 SELL) and 2.25β · 104% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile PACB is in a Breakdown options structure phase (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VVOS vs PACB
VVOS
Vivos Therapeutics, Inc. Common Stock
$0.05
-5.1% 1D
Market Cap
$1.9M
TTM Revenue
$21M
Forward P/E
N/M
Beta / 30D Vol
1.70β · 111% Vol
Unified Composite Score
36.4
SELL
Tech 25.0
Fund 35.0
Flow 50.0
Mom 30.0
Weinstein Technical Phase
Markdown · Sell / avoid
PACB
Head-to-Head Winner
Pacific Biosciences of California, Inc.
$1.63
-7.39% 1D
Market Cap
$549.5M
TTM Revenue
$161M
Forward P/E
N/M
Beta / 30D Vol
2.25β · 104% Vol
Unified Composite Score
50.1
HOLD
Tech 40.0
Fund 55.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (VVOS 3 – 2 PACB)
1. Valuation Multiples
VVOS
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.1x
7.4x
2. Growth & Scale
PACB
Revenue Growth (YoY)
+34.9%
+5.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$21M
$161M
Market Cap
$1.9M
$549.5M
3. Profitability & Quality
VVOS
Gross Margin
61.9%
27.7%
Operating Margin
-107.9%
-333.0%
Net Profit Margin
-121.8%
-81.3%
Return on Equity (ROE)
-8585.3%
-929.3%
4. Balance Sheet & Cash Flow
VVOS
Cash Generation (TTM)
-$21M EBITDA
-$150M
Cash Flow Margin
-99.3% EBITDA Mgn
-93.2%
Net Cash / Leverage
-8585.3% ROE
$649M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PACB
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
N/A (N/A)
191.0% (97th %ile)
Put/Call OI Skew
N/A
0.07x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VVOS (2) vs PACB (6)| Institutional Metric | VVOS | PACB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.9M | $549.5M | PACB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +34.9% | +5.5% | VVOS | |
| Operating Margin (TTM) | -107.9% | -333.0% | VVOS | |
| Net Profit Margin | -121.8% | -81.3% | PACB | |
| Return on Equity (ROE) | -8585.3% | -929.3% | PACB | |
| 52-Week Range Position | 0% ($0–$3) | 24% ($1–$3) | PACB | |
| Beta / 30D Volatility | 1.70β · 111% Vol | 2.25β · 104% Vol | PACB | |
| Unified Institutional Score | 36.4 / 100 (SELL) | 50.1 / 100 (HOLD) | PACB | |
| Trailing 12M Revenue (USD) | $21M | $161M | Scale | |
| Gross Profit Margin (TTM) | 61.9% | 27.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.1x EV/Rev | N/M PEG · 7.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$21M EBITDA (-8585.3% ROE) | -$150M ($649M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PACB +38.38 pp
3M Horizon
PACB +107.83 pp
6M Horizon
PACB +124.76 pp
1Y Horizon
PACB +90.32 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VVOS Revenue | PACB Revenue | VVOS Op. Margin | PACB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $80M | N/A | -128.4% | PACB |
| FY2019 | $10M | $90M | -92.8% | -110.6% | VVOS |
| FY2020 | $10M | $80M | -92.1% | -132.3% | VVOS |
| FY2021 | $20M | $130M | -120.7% | -161.2% | VVOS |
| FY2022 | $20M | $130M | -156.2% | -239.4% | VVOS |
| FY2023 | $10M | $200M | -125.3% | -166.8% | VVOS |
| FY2024 | $20M | $150M | -74.3% | -308.0% | VVOS |
| FY2025 | $20M | $160M | -114.1% | -346.2% | VVOS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VVOS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PACB
BREAKDOWN
Current IV
191.0%
IV Percentile
97th %ile
Put/Call OI Skew
0.07x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VVOS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PACB Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VVOS vs PACB Key Questions & Quantitative Answers
As of Nov 20, 2026, Pacific Biosciences of California, Inc. (PACB) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (50.1/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus PACB at $1.63 (N/M Forward P/E, -333.0% operating margin). Growth vs. Quality Trade-Off: PACB earns the overall head-to-head edge with a stronger Unified Composite Score (50.1/100 HOLD vs. VVOS 36.4/100 SELL) and 2.25β · 104% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile PACB is in a Breakdown options structure phase (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PACB leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VVOS cumulative revenue shifted +100.0% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.
VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus PACB (-929.3% ROE) capital efficiency.
In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.25β · 104% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PACB vs VVOS · Reverse Pair
PACB vs TWST
· Sector Peer
PACB vs NTLA
· Sector Peer
PACB vs CRSP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking